IRF1 and colorectal cancer: Inhibition of m6A in colorectal cancer via METTL3/4 deficiency resulted in the upregulation of IFN-γ-STAT1-IRF1 signaling through stabilizing the STAT1 and IRF1 mRNA, increasing secretion of IFN-γ, CXCL9, and CXCL10 further promoting infiltrating CD8+ T cells, contributing to the enhanced response to anti-PD-1 treatment [119].